Evidence map›Paper›PMID 17697821›Full record

ArticleThe American journal of cardiology2007

Predictors of aorto-saphenous vein bypass narrowing late after coronary artery bypass grafting.

Josep Rodés-Cabau, Alvaro Facta, Eric Larose, Robert DeLarochellière, Jean-Pierre Déry, Can Manh Nguyen, Louis Roy, Guy Proulx, Onil Gleeton, Gérald Barbeau and 4 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in The American journal of cardiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03542110 (Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03542110 phase4terminatedstarted 2018, after this paper: background citation

Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial

Ran2018Enrolled46Registered outcomes4Posted comparisons0ConditionsSaphenous Vein Graft AtherosclerosisArmsAlirocumab 150 MG/ML subcutaneous injection, Matching Placebo subcutaneous injection
Open the trial in the graph
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Saphenous vein graft interventions.Current treatment options in cardiovascular medicine · 2014 · on this map
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Josep Rodés-CabauInterventional Cardiology Laboratories, Quebec Heart Institute-Laval Hospital, Laval, Quebec, Canada. josep.rodes@crhl.ulaval.ca
Alvaro Facta
Eric Larose
Robert DeLarochellière
Jean-Pierre Déry
Can Manh Nguyen
Louis Roy
Guy Proulx
Onil Gleeton
Gérald Barbeau
Bernard Noël
Jacques Rouleau
Jean-Roch Boudreault
Olivier F Bertrand
Jewish Rehabilitation Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this study was to evaluate the clinical and angiographic factors associated with significant saphenous vein graft (SVG) atherosclerosis progression at mid-term follow-up in a series of unselected coronary patients who had previously received a coronary artery bypass graft (CABG). A total of 123 SVGs from 86 patients who underwent cardiac catheterization twice, 15 +/- 12 months apart, were included in the study. None of the SVGs presented any > or =50% diameter stenosis (DS) lesion or underwent any intervention at baseline. All SVGs were divided into 3 segments and each SVG segment was scored from 0 to 3 depending on the presence of lesions, with percent DS ranging from 0% to 19% (score 0), 20% to 29% (score 1), 30% to 39% (score 2), and > or =40% (score 3). The SVG atherosclerotic burden score (ABS) was calculated by adding the score obtained for each of the 3 SVG segments. Significant progression was defined as > or =10% increase in lesion percent DS or > or =0.6 mm decrease in minimal lumen diameter between baseline and follow-up studies. Mean age of the study population was 66 +/- 9 years, and most of the patients were receiving statin therapy with mean low-density lipoprotein cholesterol of 85 +/- 26 mg/dl. Significant angiographic progression occurred in > or =1 SVG in 41 patients (48%). On multivariate analysis, the variables associated with SVG atherosclerosis progression were SVG ABS (odds ratio [OR], 1.52 for each increase of 1 point in SVG ABS; 95% confidence interval [CI] 1.1 to 2.29) and high-density lipoprotein (HDL) cholesterol (OR 1.38 for each decrease of 5 mg/dl in HDL cholesterol levels, 95% CI 1.09 to 1.85). Twenty-two patients (26%) had a cardiac event at follow-up related to SVG disease progression. The percent DS of the SVG segment at baseline was associated with SVG disease progression leading to a cardiac event (OR 3.67 for each increase of 5% in percent DS, 95% CI 2.11 to 6.38). In conclusion, simple clinical and angiographic variables such as HDL cholesterol, ABS, and lesion severity remain independent predictors of significant SVG atherosclerosis progression in mild to moderately diseased SVGs despite mean low-density lipoprotein levels <90 mg/dl.

Indexed as

Coronary AngiographyAgedAorta, ThoracicBiomarkersCholesterol, LDLCoronary Artery BypassCoronary Artery DiseaseCoronary RestenosisCoronary StenosisDisease ProgressionFemaleFollow-Up StudiesHumansMalePrognosisRetrospective StudiesBiomarkersCholesterol, LDL

Identifiers

PMID17697821
OpenAlexW2118633850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.